drugset / Trial / NCT05294744

Utility of the Use of N-acetylcysteine Associated With Conventional Treatment in Patients With Severe Acute Alcoholic Hepatitis (Maddrey> 32)

NCT05294744

Recruiting 390 enrolled Bioaraba Health Research Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to evaluate the hypothesis that patients with severe acute alcoholic hepatitis have lower morbi-mortality if the patients receive treatment with corticosteroids + NAC, compared to patients that only receive corticosteroids.

Timeline

Start
2022-10-07
Primary completion
2026-07
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Subject N-acetylcysteine Small molecule 600 mg Intravenous

Indications